<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anxiety in schizophrenia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anxiety in schizophrenia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anxiety in schizophrenia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Samuel G Siris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raphael J Braga, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H931451436"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anxiety is frequently observed among patients with schizophrenia. Anxiety may present as a component of schizophrenia (particularly during an acute psychotic episode), a result of an underlying organic condition, a medication side effect, or a symptom of a co-occurring anxiety disorder. A thorough psychiatric examination, including a medical history and physical examination, and possibly intervention trials, may be needed to arrive at an accurate diagnosis. Treatment is based on this determination.</p><p>The epidemiology, clinical manifestations, diagnosis, and treatment of anxiety and anxiety disorders (eg, posttraumatic stress disorder, obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder) in patients with schizophrenia are discussed here. Anxiety disorders and schizophrenia as individual, noncomorbid conditions are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6962.html" rel="external">"Schizophrenia in adults: Clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/498.html" rel="external">"Obsessive-compulsive disorder in adults: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H931451443"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Schizophrenia spectrum disorders include schizophrenia, schizoaffective, schizophreniform disorder, delusional disorders, and psychosis not otherwise specified. A meta-analysis of 52 studies with a total of 4032 patients with a schizophrenia spectrum disorder found that 38.3 percent suffered from a comorbid anxiety disorder [<a href="#rid1">1</a>]. Mean prevalence rates were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Social anxiety disorder (social phobia) – 14.9 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Posttraumatic stress disorder – 12.4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Obsessive-compulsive disorder (OCD) – 12.1 percent</p><p></p><p>Rates of anxiety disorder appear to be higher among individuals with schizoaffective disorder as compared with schizophrenia (30.1 versus 16.7 percent) [<a href="#rid2">2</a>].</p><p>Disorder rates across studies are markedly heterogeneous, largely due to use of different samples, diagnostic tools, and symptom-rating instruments. Mean rates are higher than those found for anxiety disorders in the general population. Additionally, studies suggest that individuals with an early age of schizophrenia onset have a higher prevalence of anxiety than individuals with later onset and the presence of anxiety disorders in patients with first episode psychosis has been associated with poorer initial outcomes [<a href="#rid3">3,4</a>].</p><p>Furthermore, an analysis of data from the Epidemiologic Catchment Area study found that the presence of OCD, social phobia, or panic attacks were associated with a 2.6 to 3.5 increased odds of developing schizophrenia [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H931451450"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Little is known regarding the pathophysiology of anxiety in schizophrenia.</p><p class="headingAnchor" id="H1128051247"><span class="h2">Neurobiology</span><span class="headingEndMark"> — </span>Imaging and postmortem studies suggest that dysregulation of the major neurotransmitters, such as dopamine, glutamate, and serotonin may contribute to the presence of anxiety symptoms in schizophrenia [<a href="#rid6">6</a>].</p><p>Some evidence suggests that the identification of neural abnormalities involved in anxiety, schizophrenia and schizophrenia with comorbid anxiety may lead to improved diagnosis and management of these conditions. In a magnetic resonance imaging (MRI) study, gray matter volume changes in 80 subjects with schizophrenia, symptomatic anxiety, schizophrenia with comorbid anxiety, and healthy controls (n = 20 each group) were compared. Subjects with schizophrenia with comorbid anxiety had volumes comparable to control subject and showed less gray matter volume decreases in the dorsolateral prefrontal cortex and precentral gyrus than those with schizophrenia only. Subjects in the schizophrenia group showed reduced gray matter volumes in the dorsolateral prefrontal cortex, precentral gyrus, orbitofrontal cortex, temporal gyrus and inferior parietal gyrus as compared with subjects in the control group [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H657661641"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>Familial aggregation of obsessive-compulsive-associated disorders (ie, obsessive-compulsive disorder [OCD], obsessive-compulsive personality disorder, and schizophrenia with comorbid obsessive symptoms) has been reported, such that relatives of schizophrenia patients with OCD have higher rates of anxiety disorders than relatives of schizophrenia probands without OCD [<a href="#rid8">8</a>]. This provides support for the validity of the OCD as a discrete comorbid entity [<a href="#rid9">9,10</a>]. However, these findings are derived from small samples.</p><p class="headingAnchor" id="H931451457"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Anxiety is theorized to perform the important signal function of alerting the individual to danger. An example is the anxiety that alerts a person to look both ways before crossing the street. When the anxiety is unduly severe, in the absence of sufficient cause, or lasts longer than reasonable it is considered a symptom. Symptoms of anxiety may include excessive or persistent worry, restlessness, hyperarousal, fatigue, irritability, poor concentration, sleep disturbance, and muscle tension. These symptoms may lead to distress and deficits in psychosocial functioning.</p><p>Symptoms of anxiety in patients with schizophrenia can be secondary to schizophrenia or independent of the psychotic disorder.</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety as a secondary symptom presents as an integral part of an active psychotic process. An example is a patient experiencing anxiety induced by terrifying hallucinations and delusions. Anxiety secondary to psychosis tends to improve as psychosis improves (eg, in response to antipsychotic treatment).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety can persist in the form of a syndrome or disorder that co-occurs independently from schizophrenia. Specific anxiety disorders can present with different degrees of overlap with the psychotic symptoms of schizophrenia. As examples, panic and paranoia both involve extreme states of fear. It has been proposed that the affective storm of anxiety during a panic attack can spur a patient with schizophrenia to scan their environment for danger that would justify the anxiety [<a href="#rid11">11</a>]. A paranoid individual may experience an exaggerated perception of danger in their environment as a complement to the extreme anxiety of the panic attack. Obsessions in obsessive-compulsive disorder (OCD) can overlap conceptually with delusions in schizophrenia. It can be the inability of a patient to get a delusional thought off their mind, rather than the incorrectness of the thought, which causes much of the patient’s suffering and functional impairment [<a href="#rid12">12</a>].</p><p></p><p>Anxiety may be present prior to the occurrence of schizophrenia or may persist in the absence of psychosis. Anxiety is often a feature in the prodrome leading to schizophrenia [<a href="#rid13">13</a>]. Studies suggests that anxiety is more prevalent in individuals with an earlier rather than later age of schizophrenia onset. (See <a class="local">'Epidemiology'</a> above.)</p><p>Anxiety disorders including OCD, panic disorder, posttraumatic stress disorder, generalized anxiety disorder, specific phobias, and social anxiety disorder, and their distinguishing features [<a href="#rid14">14</a>] are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14637.html" rel="external">"Specific phobia in adults: Epidemiology, clinical manifestations, course, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14637.html" rel="external">"Specific phobia in adults: Epidemiology, clinical manifestations, course, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14637.html" rel="external">"Specific phobia in adults: Epidemiology, clinical manifestations, course, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/498.html" rel="external">"Obsessive-compulsive disorder in adults: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H24353553"><span class="h1">COURSE</span><span class="headingEndMark"> — </span>Patients with anxiety predating schizophrenia have been found to have worse outcomes compared with patients with anxiety that developed as part of the psychotic process [<a href="#rid15">15,16</a>]. High levels of anxiety symptoms or the presence of an anxiety disorder have been associated with more severe positive symptoms of schizophrenia, social withdrawal, depression, hopelessness, increased suicide rates, and poorer functioning [<a href="#rid9">9,10</a>]. Studies of patients with co-occurring schizophrenia and anxiety disorders have found that patients with anxiety disorders had increased service utilization and hospitalization rates compared with patients without an anxiety disorder [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H24352241"><span class="h1">ASSESSMENT</span><span class="headingEndMark"> — </span>We find that the assessment of anxiety can be difficult when attempted in a single cross-sectional evaluation. We often find it is necessary to repeat the history and examination over an extended period of time to establish an accurate diagnosis. In patients with schizophrenia presenting with anxiety, the assessment and management of the anxiety are closely intertwined. The diagnosis of anxiety as a component of schizophrenia or an anxiety disorder is a diagnosis of exclusion. We rule out organic causes, including medication side effects as possible etiology of the symptoms.</p><p class="headingAnchor" id="H639774819"><span class="h2">History and examination</span><span class="headingEndMark"> — </span>We take a detailed history and physical examination, review of medications and adherence. We typically send for laboratories including complete blood count and metabolic panel including calcium and thyroid function tests to assess for underlying causes of anxiety in patients with schizophrenia. If panic attacks are part of the differential diagnosis, concern about a potential pheochromocytoma or arrhythmia can prompt referral to a medical generalist or specialist.</p><p class="headingAnchor" id="H723486155"><span class="h2">Rating scale</span><span class="headingEndMark"> — </span>The Staden Schizophrenia Anxiety Rating Scale, a validated tool for the assessment of anxiety in schizophrenia, is available for assessment of anxiety in individuals with schizophrenia [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H24355620"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Assessment and management are guided by the differential diagnosis and determination of the likely source of anxiety or anxiety-like symptoms. We try to distinguish between anxiety as a symptom of schizophrenia and a distinct anxiety disorder. We consider the following as potential causes of anxiety in individuals with schizophrenia: </p><p class="headingAnchor" id="H2763095496"><span class="h3">Anxiety as a symptom of schizophrenia</span><span class="headingEndMark"> — </span>The presence of anxiety with an acute psychotic episode can increase the severity of the patient’s clinical status and the difficulty of clinical management. The phenomenological distinction between symptoms of anxiety disorders and psychotic symptoms can be often difficult to determine. We are vigilant to the temporal and clinical relationship between anxiety and psychotic symptoms. During acute psychotic breaks differentiating these relationships can be very difficult.</p><p class="bulletIndent1"><span class="glyph">●</span>In a patient presenting with panic attacks, untriggered attacks are suggestive of a panic disorder, while panic accompanying the persecutory delusions of schizophrenia does not suggest an independent anxiety disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The avoidance inherent in social anxiety can overlap phenomenologically with negative symptoms of schizophrenia (eg, a lack of interest in social activities). A patient avoiding social situations may have a comorbid social anxiety disorder, suggested by the presence of discomfort with social exposure, or may lack interest in social situations, a common negative symptom of schizophrenia. Social avoidance can also be due to active positive symptoms. As an example, a patient might avoid social interaction for delusional fear of persecution. Such cases should be distinguished from comorbid social anxiety disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obsessions in obsessive-compulsive disorder can overlap with delusions in schizophrenia [<a href="#rid12">12</a>]. It can be the inability of a psychotic patient to get delusional thoughts off their mind, rather than the content of the thought itself, that causes much of the patient’s suffering and functional impairment.</p><p></p><p class="headingAnchor" id="H3144599901"><span class="h3">Side effect of antipsychotic or other medication</span><span class="headingEndMark"> — </span>Medications taken may cause anxiety like symptoms. These are listed on the table  (<a class="graphic graphic_table graphicRef54521" href="/d/graphic/54521.html" rel="external">table 1</a>). Antipsychotic medications can lead to akathisia or obsessive-compulsive symptoms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Akathisia</strong> – Akathisia is an extrapyramidal symptom that may present with fidgetiness, internal angst, motor restlessness, and inability to sit still. In milder cases the patient may describe a subjective feeling of restlessness but not show restless motor behavior. Akathisia and its treatments are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Akathisia'</a> and  <a class="medical medical_review" href="/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/d/html/14773.html" rel="external">"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obsessive-compulsive symptoms</strong> – De novo obsessive and compulsive symptoms can accompany initiation of a second-generation antipsychotic drug [<a href="#rid19">19</a>]. Data suggest that the symptoms increase with antipsychotic dose. A temporal association between medication initiation (or dose increase) and symptom onset can help to identify these side effects. However, the symptoms may develop weeks or months after medication initiation. The side effects are thought to be caused by the 5-HT2a antagonism of most second-generation antipsychotics. Treatment of obsessional or compulsive symptoms in individuals treated with antipsychotic medications are discussed below. (See <a class="local">'Anxiety related to medication effects'</a> below.)</p><p></p><p class="headingAnchor" id="H786164038"><span class="h3">Co-occurring anxiety disorder</span><span class="headingEndMark"> — </span>A co-occurring anxiety disorder can be diagnosed in patients with schizophrenia if the patient fully meets the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for the disorder and if the alternative possibilities, described above, have been ruled out [<a href="#rid14">14</a>]. While this may be clear cut in some cases, it may be more ambiguous in others. DSM-5 criteria require that the current anxiety symptoms are “not better accounted for by another mental disorder.” This judgment is left to the individual clinician and may be less than obvious in some cases. Anxiety disorders are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14637.html" rel="external">"Specific phobia in adults: Epidemiology, clinical manifestations, course, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14637.html" rel="external">"Specific phobia in adults: Epidemiology, clinical manifestations, course, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14637.html" rel="external">"Specific phobia in adults: Epidemiology, clinical manifestations, course, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/498.html" rel="external">"Obsessive-compulsive disorder in adults: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H1489822988"><span class="h3">Medically related causes</span><span class="headingEndMark"> — </span>Many medical conditions can generate or mimic anxiety symptoms in patients with schizophrenia, including current medical illnesses and substance use disorders, including withdrawal. See table for medical conditions that can cause anxiety or symptoms that can be mistaken for anxiety  (<a class="graphic graphic_table graphicRef58758" href="/d/graphic/58758.html" rel="external">table 2</a>). Individuals with schizophrenia have higher rates compared with the general population of such medical conditions, including cardiovascular and pulmonary disease [<a href="#rid20">20</a>] and substance use disorders [<a href="#rid21">21,22</a>]. (See  <a class="medical medical_review" href="/d/html/7798.html" rel="external">"Co-occurring schizophrenia and substance use disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment and diagnosis"</a>.)</p><p class="headingAnchor" id="H3944559105"><span class="h1">MANAGEMENT OF ANXIETY IN SCHIZOPHRENIA</span></p><p class="headingAnchor" id="H4008459867"><span class="h2">Anxiety as a symptom of schizophrenia</span><span class="headingEndMark"> — </span>Differentiating anxiety as a symptom of schizophrenia versus comorbid anxiety with schizophrenia can be difficult. Additionally, worsening anxiety has been described as a side effect of antipsychotic medications. In some cases, adjustment of the antipsychotic dose can be helpful in determining the diagnosis. In cases where the antipsychotic dose is increased and the anxiety and psychosis resolve, the response suggests that anxiety was a symptom of schizophrenia [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H3282909452"><span class="h2">Anxiety related to medication effects</span></p><p class="headingAnchor" id="H423000595"><span class="h3">Obsessive-compulsive symptoms</span><span class="headingEndMark"> — </span>In patients with anxiety (eg, obsessive-compulsive symptoms) secondary to second-generation medication, we individualize the treatment depending on the clinical presentation. When feasible (eg, low risk of exacerbation of psychosis), we decreased the antipsychotic medication by approximately 25 percent and monitor closely. If this is not feasible or does not result in improvement, we consider switching antipsychotics, possibly to one with less serotonin antagonism, such as <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a>.</p><p>A change in antipsychotic medication may not be an option when the patient is taking <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a>, because this drug is typically used in patients with schizophrenic symptoms refractory to other antipsychotics. Case reports have suggested that selective serotonin reuptake inhibitors (SSRIs) may reduce clozapine-induced obsessive and compulsive symptoms [<a href="#rid24">24-26</a>]. However, it should be noted that controlled studies are lacking, and the risks of additional side effects should be weighed against potential benefits of adding an SSRI. Some SSRIs (especially <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a>) interact with clozapine, leading to toxic clozapine levels in some individuals [<a href="#rid27">27</a>]. Fluvoxamine should be avoided in patients receiving clozapine. Other SSRIs should be used with caution and accompanied by monitoring of clozapine drug levels. (See  <a class="medical medical_review" href="/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p class="headingAnchor" id="H1732735541"><span class="h3">Akathisia</span><span class="headingEndMark"> — </span>Treatment of akathisia is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Akathisia'</a>.)</p><p class="headingAnchor" id="H563610845"><span class="h2">Co-occurring schizophrenia and anxiety disorder</span><span class="headingEndMark"> — </span>Although not empirically tested in schizophrenia and varying by anxiety disorder, we often used a combined modality approach with medication and cognitive-behavioral therapy (CBT). Combination therapy may be more effective than either of the individual modalities.</p><p class="headingAnchor" id="H1857618869"><span class="h3">Pharmacotherapy</span><span class="headingEndMark"> — </span>In most cases of co-occurring schizophrenia with anxiety disorder, our preference is pharmacologic management based on treatment recommendations for anxiety in the noncomorbid population. Minimal data (eg, small randomized trials, open trials, case reports) is available on treatment of comorbid anxiety and schizophrenia [<a href="#rid28">28-36</a>].</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obsessive-compulsive disorder (OCD)</strong> – Two small randomized trials have found the serotonergic antidepressants <a class="drug drug_general" data-topicid="9283" href="/d/drug information/9283.html" rel="external">clomipramine</a> and <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> to reduce OCD symptoms in patients with schizophrenia compared with placebo [<a href="#rid28">28</a>]. These findings have been supported by case reports suggesting efficacious treatment with <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, fluvoxamine, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>. (See  <a class="medical medical_review" href="/d/html/14629.html" rel="external">"Management of obsessive-compulsive disorder in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Panic disorder/attacks </strong>– Case reports and open trials have reported reductions in panic attacks in patients with comorbid schizophrenia and panic disorder treated with <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>, and <a class="drug drug_general" data-topicid="8554" href="/d/drug information/8554.html" rel="external">imipramine</a> [<a href="#rid29">29-31</a>]. A few case reports have suggested panic attacks respond to changes from a first- to second-generation antipsychotic [<a href="#rid32">32,33</a>]. No studies were found of SSRIs for panic in schizophrenia. (See  <a class="medical medical_review" href="/d/html/108804.html" rel="external">"Management of panic disorder with or without agoraphobia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Social anxiety disorder </strong>– A small open trial suggested that <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> may be effective for patients with schizophrenia and social phobia [<a href="#rid34">34</a>]. Sixteen patients had their existing antipsychotics cross titrated with aripiprazole and were then followed for two months. The change to aripiprazole was associated with a reduction of social anxiety after three weeks of treatment. These results have not been replicated. (See  <a class="medical medical_review" href="/d/html/505.html" rel="external">"Pharmacotherapy for social anxiety disorder in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other anxiety or disorders</strong> – No published trials or case reports are available to evaluate the efficacy of pharmacotherapy for posttraumatic stress disorder (PTSD), generalized anxiety disorder, or phobias other than social anxiety in patients with schizophrenia. (See  <a class="medical medical_review" href="/d/html/101879.html" rel="external">"Generalized anxiety disorder in adults: Management"</a> and  <a class="medical medical_review" href="/d/html/117909.html" rel="external">"Posttraumatic stress disorder in adults: Treatment overview"</a> and  <a class="medical medical_review" href="/d/html/114843.html" rel="external">"Specific phobia in adults: Treatment overview"</a>.)</p><p></p><p class="bulletIndent1">Small trials or retrospective chart reviews have shown mixed results in the treatment of schizophrenia with anxiety [<a href="#rid35">35,36</a>]. </p><p></p><p>Treatment of SSRIs in individuals on antipsychotic medications may result in changes in antipsychotic blood levels. Treatment of anxiety and specific anxiety disorders with SSRIs are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Drug-drug interactions'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Drug-drug interactions'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14637.html" rel="external">"Specific phobia in adults: Epidemiology, clinical manifestations, course, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Drug-drug interactions'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2783216537"><span class="h3">Cognitive-behavioral therapy</span><span class="headingEndMark"> — </span>For patients with co-occurring panic disorder, social anxiety disorder, or PTSD who have not responded adequately to medication, we suggest a trial of adjunctive CBT. (See  <a class="medical medical_review" href="/d/html/15774.html" rel="external">"Schizophrenia in adults: Psychosocial management"</a>.)</p><p>Limited evidence suggests that CBT may be efficacious in reducing symptoms of anxiety disorders in patients with co-occurring schizophrenia, including two small trials of patients with social anxiety disorder [<a href="#rid37">37,38</a>] and a small open trial of patients with panic disorder [<a href="#rid39">39</a>]. Stronger evidence supports the use of CBT for PTSD in patients with schizophrenia [<a href="#rid40">40,41</a>].</p><p>As an example, in a trial 155 subjects with co-occurring PTSD and a psychotic disorder (90 percent with schizophrenia or schizoaffective disorder) were randomly assigned to receive eight 90-minute sessions of one either prolonged exposure, eye movement desensitization and reprocessing therapy (EMDR), or waitlist (control) [<a href="#rid41">41</a>]. At the end of the treatment period and at six-month follow-up, groups who received exposure therapy or EDMR therapy experienced less severe PTSD symptoms and had lower rates of participants continuing to meet PTSD diagnostic criteria compared with the control group (57 and 60 versus 27 percent). Additionally, participants receiving exposure therapy, but not those receiving EMDR, were more likely to meet criteria for full remission of PTSD compared with the control group (28.3 and 16.4 versus 6.4 percent). There were no differences in severe adverse events among groups.</p><p>In cases where specific situations or interpersonal interactions are identified as closely related to the onset of anxiety, the patient may benefit from supportive therapeutic techniques, building of the patient’s coping skills, or family interventions [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/15774.html" rel="external">"Schizophrenia in adults: Psychosocial management"</a>.)</p><p>Treatment of anxiety disorders with cognitive therapies are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/14632.html" rel="external">"Generalized anxiety disorder in adults: Cognitive-behavioral therapy and other psychotherapies"</a> and  <a class="medical medical_review" href="/d/html/14635.html" rel="external">"Social anxiety disorder in adults: Psychotherapy"</a> and  <a class="medical medical_review" href="/d/html/14633.html" rel="external">"Psychotherapy for panic disorder with or without agoraphobia in adults"</a> and  <a class="medical medical_review" href="/d/html/16126.html" rel="external">"Specific phobia in adults: Cognitive-behavioral therapy"</a> and  <a class="medical medical_review" href="/d/html/14634.html" rel="external">"Posttraumatic stress disorder in adults: Psychotherapy and psychosocial interventions"</a>.)</p><p class="headingAnchor" id="H2265490811"><span class="h2">Medical causes</span><span class="headingEndMark"> — </span>We address medical causes, such as hyperthyroidism, which are thought to be causing anxiety in individuals with schizophrenia.</p><p class="headingAnchor" id="H904720944"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117525.html" rel="external">"Society guideline links: Psychotic disorders"</a>.)</p><p class="headingAnchor" id="H931451493"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anxiety in schizophrenia</strong> – Anxiety is frequently observed among patients with schizophrenia. The presence of anxiety with an acute psychotic episode can increase the severity of the patient’s clinical status and the difficulty of clinical management. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Symptoms of anxiety may include excessive or persistent worry, restlessness, hyperarousal, fatigue, irritability, poor concentration, sleep disturbance, and muscle tension. These symptoms may lead to distress and deficits in psychosocial functioning. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Course</strong> – High levels of anxiety symptoms or the presence of an anxiety disorder have been associated with more severe positive symptoms of schizophrenia, social withdrawal, depression, hopelessness, increased suicide rates, and poorer functioning. Additionally, increased service utilization and hospitalization rates are reported. (See <a class="local">'Course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>–<strong> </strong>We consider the following as potential causes of anxiety in individuals with schizophrenia: (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anxiety as a symptom of schizophrenia </strong>– The phenomenological distinction between symptoms of anxiety disorders and psychotic symptoms can be often difficult to determine. We are vigilant to the temporal and clinical relationship between anxiety and psychotic symptoms. (See <a class="local">'Anxiety as a symptom of schizophrenia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medication side effect</strong> – Akathisia and obsessive compulsive symptoms may be cause by antipsychotic medications. (<a class="graphic graphic_table graphicRef54521" href="/d/graphic/54521.html" rel="external">table 1</a>). (See <a class="local">'Anxiety related to medication effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Co-occurring schizophrenia with anxiety disorder </strong>– In cases of co-occurring disorders, we cautiously typically treat the anxiety disorder pharmacologically, based on treatment recommendations for anxiety in the noncomorbid population. (See <a class="local">'Co-occurring anxiety disorder'</a> above.)</p><p></p><p class="bulletIndent2">We suggest a trial of adjunctive cognitive-behavioral therapy for patients with schizophrenia and co-occurring panic disorder, social anxiety disorder, or posttraumatic stress disorder who have not responded adequately to treatment with medication (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medically related causes</strong> – We use detailed history, examination and laboratory data including metabolic panel, thyroid functions, complete blood count to rule out medical causes of anxiety in schizophrenia  (<a class="graphic graphic_table graphicRef58758" href="/d/graphic/58758.html" rel="external">table 2</a>). (See <a class="local">'Medically related causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of anxiety in schizophrenia </strong>– Our management of anxiety in individuals with schizophrenia is guided by our use of the differential diagnosis to determine the most likely cause. The causes are addressed with pharmacologic changes, psychotherapy or addressing medical causes. (See <a class="local">'Management of anxiety in schizophrenia'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Achim AM, Maziade M, Raymond E, et al. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 2011; 37:811.</a></li><li><a class="nounderline abstract_t">Young S, Pfaff D, Lewandowski KE, et al. Anxiety disorder comorbidity in bipolar disorder, schizophrenia and schizoaffective disorder. Psychopathology 2013; 46:176.</a></li><li><a class="nounderline abstract_t">Strakowski SM, Tohen M, Stoll AL, et al. Comorbidity in psychosis at first hospitalization. Am J Psychiatry 1993; 150:752.</a></li><li><a class="nounderline abstract_t">Craig T, Hwang MY, Bromet EJ. Obsessive-compulsive and panic symptoms in patients with first-admission psychosis. Am J Psychiatry 2002; 159:592.</a></li><li><a class="nounderline abstract_t">Tien AY, Eaton WW. Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome. Arch Gen Psychiatry 1992; 49:37.</a></li><li><a class="nounderline abstract_t">Muller JE, Koen L, Soraya S, et al. Anxiety disorders and schizophrenia. Curr Psychiatry Rep 2004; 6:255.</a></li><li><a class="nounderline abstract_t">Picado M, Carmona S, Hoekzema E, et al. The neuroanatomical basis of panic disorder and social phobia in schizophrenia: a voxel based morphometric study. PLoS One 2015; 10:e0119847.</a></li><li><a class="nounderline abstract_t">Poyurovsky M, Kriss V, Weisman G, et al. Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD. Am J Med Genet B Neuropsychiatr Genet 2005; 133B:31.</a></li><li><a class="nounderline abstract_t">Braga RJ, Mendlowicz MV, Marrocos RP, Figueira IL. Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life. J Psychiatr Res 2005; 39:409.</a></li><li><a class="nounderline abstract_t">Lysaker PH, Salyers MP. Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history. Acta Psychiatr Scand 2007; 116:290.</a></li><li><a class="nounderline abstract_t">Bermanzohn PC, Arlow PB, Albert C, Siris SG. Relationship of panic attacks to paranoia. Am J Psychiatry 1999; 156:1469.</a></li><li><a class="nounderline abstract_t">Berman I, Merson A, Viegner B, et al. Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study. J Nerv Ment Dis 1998; 186:150.</a></li><li><a class="nounderline abstract_t">Shioiri T, Shinada K, Kuwabara H, Someya T. Early prodromal symptoms and diagnoses before first psychotic episode in 219 inpatients with schizophrenia. Psychiatry Clin Neurosci 2007; 61:348.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.</li><li><a class="nounderline abstract_t">Fenton WS, McGlashan TH. The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 1986; 143:437.</a></li><li><a class="nounderline abstract_t">Hwang MY, Morgan JE, Losconzcy MF. Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study. J Neuropsychiatry Clin Neurosci 2000; 12:91.</a></li><li><a class="nounderline abstract_t">Birgenheir DG, Ganoczy D, Bowersox NW. Service utilization among veterans with schizophrenia and a comorbid anxiety disorder. Psychiatr Serv 2014; 65:1354.</a></li><li><a class="nounderline abstract_t">Van Staden W, Dlagnekova A, Naidu K. Validity and Reliability of the Staden Schizophrenia Anxiety Rating Scale. Diagnostics (Basel) 2022; 12.</a></li><li><a class="nounderline abstract_t">Kim SW, Shin IS, Kim JM, et al. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. Clin Neuropharmacol 2009; 32:224.</a></li><li><a class="nounderline abstract_t">Druss BG, Bradford WD, Rosenheck RA, et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001; 58:565.</a></li><li><a class="nounderline abstract_t">Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002; 59:115.</a></li><li><a class="nounderline abstract_t">de Leon J, Tracy J, McCann E, et al. Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. Schizophr Res 2002; 56:55.</a></li><li><a class="nounderline abstract_t">Yamaguchi H, Takahashi A, Takano A, Kojima T. Direct effects of short-term psychoeducational intervention for relatives of patients with schizophrenia in Japan. Psychiatry Clin Neurosci 2006; 60:590.</a></li><li><a class="nounderline abstract_t">Allen L, Tejera C. Treatment of clozapine-induced obsessive-compulsive symptoms with sertraline. Am J Psychiatry 1994; 151:1096.</a></li><li><a class="nounderline abstract_t">Poyurovsky M, Hermesh H, Weizman A. Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients. Clin Neuropharmacol 1996; 19:305.</a></li><li><a class="nounderline abstract_t">Rahman MS, Grace JJ, Pato MT, Priest B. Sertraline in the treatment of clozapine-induced obsessive-compulsive behavior. Am J Psychiatry 1998; 155:1629.</a></li><li><a class="nounderline abstract_t">Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153:820.</a></li><li><a class="nounderline abstract_t">Braga RJ, Petrides G, Figueira I. Anxiety disorders in schizophrenia. Compr Psychiatry 2004; 45:460.</a></li><li><a class="nounderline abstract_t">Figueira I, Mendlowicz M, Nardi AE, et al. Social phobia and panic disorder in psychotic patients: Psychopharmacology series 6. J Bras Psiq 1992; 41:259.</a></li><li><a class="nounderline abstract_t">Kahn JP, Puertollano MA, Schane MD, Klein DF. Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications. Am J Psychiatry 1988; 145:742.</a></li><li><a class="nounderline abstract_t">Siris SG, Aronson A, Sellew AP. Imipramine-responsive panic-like symptomatology in schizophrenia/schizoaffective disorder. Biol Psychiatry 1989; 25:485.</a></li><li><a class="nounderline abstract_t">Takahashi H, Higuchi H, Shimizu T. Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone. J Neuropsychiatry Clin Neurosci 2001; 13:113.</a></li><li><a class="nounderline abstract_t">Takahashi H, Sugita T, Yoshida K, et al. Effect of quetiapine in the treatment of panic attacks in patients with schizophrenia: 3 case reports. J Neuropsychiatry Clin Neurosci 2004; 16:113.</a></li><li><a class="nounderline abstract_t">Stern RG, Petti TA, Bopp K, Tobia A. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. J Clin Psychopharmacol 2009; 29:206.</a></li><li><a class="nounderline abstract_t">Schjerning O, Damkier P, Lykkegaard SE, et al. Pregabalin for anxiety in patients with schizophrenia - A randomized, double-blind placebo-controlled study. Schizophr Res 2018; 195:260.</a></li><li><a class="nounderline abstract_t">Siwek M, Chrobak AA, Gorostowicz A, et al. Lurasidone Augmentation of Clozapine in Schizophrenia-Retrospective Chart Review. Brain Sci 2023; 13.</a></li><li><a class="nounderline abstract_t">Halperin S, Nathan P, Drummond P, Castle D. A cognitive-behavioural, group-based intervention for social anxiety in schizophrenia. Aust N Z J Psychiatry 2000; 34:809.</a></li><li><a class="nounderline abstract_t">Kingsep P, Nathan P, Castle D. Cognitive behavioural group treatment for social anxiety in schizophrenia. Schizophr Res 2003; 63:121.</a></li><li><a class="nounderline abstract_t">Arlow PB, Moran ME, Bermanzohn PC, et al. Cognitive-behavioral treatment of panic attacks in chronic schizophrenia. J Psychother Pract Res 1997; 6:145.</a></li><li><a class="nounderline abstract_t">Frueh BC, Grubaugh AL, Cusack KJ, et al. Exposure-based cognitive-behavioral treatment of PTSD in adults with schizophrenia or schizoaffective disorder: a pilot study. J Anxiety Disord 2009; 23:665.</a></li><li><a class="nounderline abstract_t">van den Berg DP, de Bont PA, van der Vleugel BM, et al. Prolonged exposure vs eye movement desensitization and reprocessing vs waiting list for posttraumatic stress disorder in patients with a psychotic disorder: a randomized clinical trial. JAMA Psychiatry 2015; 72:259.</a></li></ol></div><div id="topicVersionRevision">Topic 15259 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19959704" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22906962" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Anxiety disorder comorbidity in bipolar disorder, schizophrenia and schizoaffective disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8480821" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Comorbidity in psychosis at first hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11925297" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Obsessive-compulsive and panic symptoms in patients with first-admission psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728250" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15260940" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Anxiety disorders and schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25774979" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The neuroanatomical basis of panic disorder and social phobia in schizophrenia: a voxel based morphometric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15635656" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804391" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17803759" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10484965" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Relationship of panic attacks to paranoia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521350" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17610658" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Early prodromal symptoms and diagnoses before first psychotic episode in 219 inpatients with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17610658" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Early prodromal symptoms and diagnoses before first psychotic episode in 219 inpatients with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3953886" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The prognostic significance of obsessive-compulsive symptoms in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10678519" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25022515" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Service utilization among veterans with schizophrenia and a comorbid anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35453879" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Validity and Reliability of the Staden Schizophrenia Anxiety Rating Scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644229" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11386985" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Quality of medical care and excess mortality in older patients with mental disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11825131" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12084420" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16958943" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Direct effects of short-term psychoeducational intervention for relatives of patients with schizophrenia in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8010373" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of clozapine-induced obsessive-compulsive symptoms with sertraline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8828993" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9812137" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sertraline in the treatment of clozapine-induced obsessive-compulsive behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633698" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15526257" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Anxiety disorders in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Social phobia and panic disorder in psychotic patients: Psychopharmacology series 6</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2897166" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2649158" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Imipramine-responsive panic-like symptomatology in schizophrenia/schizoaffective disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207340" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14990767" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of quetiapine in the treatment of panic attacks in patients with schizophrenia: 3 case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19440071" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28919128" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pregabalin for anxiety in patients with schizophrenia - A randomized, double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36979255" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lurasidone Augmentation of Clozapine in Schizophrenia-Retrospective Chart Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11037367" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A cognitive-behavioural, group-based intervention for social anxiety in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12892866" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cognitive behavioural group treatment for social anxiety in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9071665" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cognitive-behavioral treatment of panic attacks in chronic schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19342194" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Exposure-based cognitive-behavioral treatment of PTSD in adults with schizophrenia or schizoaffective disorder: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25607833" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prolonged exposure vs eye movement desensitization and reprocessing vs waiting list for posttraumatic stress disorder in patients with a psychotic disorder: a randomized clinical trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
